|
|
 Previous Article | Table of Contents | Next Article 
Effect of granulocyte-macrophage colony-stimulating factor on
lymphokine-activated killer cell induction
AM Stewart-Akers, JS Cairns, DJ Tweardy and SA McCarthy
Department of Molecular Genetics and Biochemistry, University of
Pittsburgh, PA 15213.
The treatment of cancer with lymphokine-activated killer (LAK) cells in
conjunction with high-dose interleukin-2 (IL-2) has been limited by the
toxicity of IL-2 and the narrow range of tumors that respond to therapy.
Cytokines that are capable of augmenting lower doses of IL-2 are,
therefore, a major focus of research. We report here that
granulocyte-macrophage colony-stimulating factor (GM-CSF) can augment
low-dose IL-2 LAK induction from murine splenocytes. Anti-tumor necrosis
factor alpha (anti-TNF alpha) or anti-interferon gamma (anti- IFN gamma)
monoclonal antibodies did not inhibit (IL-2 + GM-CSF)- induced LAK
generation, indicating that GM-CSF augmentation does not require TNF alpha
or IFN gamma activity. Depletion of natural killer cells before culture did
not inhibit low-dose IL-2-induced LAK generation or the ability of GM-CSF
to augment LAK generation. In contrast, depletion of both CD4+ and CD8+ T
cells before culture inhibited the generation of LAK activity. However,
depletion of only CD4+ T cells, or only CD8+ T cells, did not inhibit the
generation of IL-2 or (IL-2 + GM-CSF) LAK activity. These results suggest
that LAK precursors are present in both the CD4+ and CD8+ T-cell
populations and suggest that the addition of GM-CSF to low-dose IL-2 may
result in the generation of T-derived LAK cells.
Volume 81,
Issue 10,
pp. 2671-2678,
05/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. C. de Gast, F. A. Vyth-Dreese, W. Nooijen, C. J.C. van den Bogaard, J. Sein, M. M.J. Holtkamp, G. A.M. Linthorst, J. W. Baars, J. H. Schornagel, and S. Rodenhuis
Reinfusion of Autologous Lymphocytes With Granulocyte-Macrophage Colony-Stimulating Factor Induces Rapid Recovery of CD4+ and CD8+ T Cells After High-Dose Chemotherapy for Metastatic Breast Cancer
J. Clin. Oncol.,
January 1, 2002;
20(1):
58 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. de Gast, H.-J. Klümpen, F. A. Vyth-Dreese, M.-J. Kersten, N. C. V. Verra, J. Sein, D. Batchelor, W. J. Nooijen, and J. H. Schornagel
Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma
Clin. Cancer Res.,
April 1, 2000;
6(4):
1267 - 1272.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. O. Armitage
Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor
Blood,
December 15, 1998;
92(12):
4491 - 4508.
[Full Text]
[PDF]
|
|
|
|
|
